Supplementary MaterialsResearch summary. IDH2 mutants9,10. Inside a phase I/II medical trial, enasidenib inhibited 2HG production and induced medical reactions in relapsed/refractory IDH2-mutant AML11. Here we describe two individuals with IDH2-mutant AML who experienced a medical response to enasidenib followed by medical resistance, disease progression, and recurrent elevation in circulating 2HG. We found that restorative resistance… Continue reading Supplementary MaterialsResearch summary. IDH2 mutants9,10. Inside a phase I/II medical trial,